BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 24848934)

  • 1. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
    Fukumoto S
    Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].
    Kinoshita Y; Fukumoto S
    Clin Calcium; 2014 Aug; 24(8):1217-22. PubMed ID: 25065874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome.
    Takeyari S; Yamamoto T; Kinoshita Y; Fukumoto S; Glorieux FH; Michigami T; Hasegawa K; Kitaoka T; Kubota T; Imanishi Y; Shimotsuji T; Ozono K
    Bone; 2014 Oct; 67():56-62. PubMed ID: 24982027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia.
    Kinoshita Y; Hori M; Taguchi M; Fukumoto S
    Bone; 2014 Oct; 67():145-51. PubMed ID: 25026495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
    Kinoshita Y; Saito T; Shimizu Y; Hori M; Taguchi M; Igarashi T; Fukumoto S; Fujita T
    Eur J Endocrinol; 2012 Aug; 167(2):165-72. PubMed ID: 22577109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhitibion of FGF23 activities as a possible new treatment for patients with FGF23-related hypophosphatemic diseases].
    Kinoshita Y
    Clin Calcium; 2016 Feb; 26(2):233-9. PubMed ID: 26813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic role of Fgf23 in Dmp1-null mice.
    Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteocytes and the pathogenesis of hypophosphatemic rickets.
    Yamazaki M; Michigami T
    Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
    Fukumoto S
    Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 and Associated Disorders of Phosphate Wasting.
    Gohil A; Imel EA
    Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
    Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FGF23-related hypophosphatemic rickets/osteomalacia].
    Ito N; Fukumoto S
    Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.